Filters
Extraction of Liver Conditions in Enzalutamide Treated by Enzalutamide - Causes
Enzalutamide is one of the new treatment options for patients with metastatic with good tolerance. The less common symptoms of enzalutamide toxicity include nervous% of cases). The basis for this complication is the fact that en...
Oncology
- 2017 •
- O
Rok uplatnění
O - Ostatní výsledky
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
Enzalutamide is an androgen receptor (AR) inhibitor approved for therapy three different cellular models of enzalutamide resistance including a cell line of enzalutamide was achieved. When compared to controls, resistant ce...
FD - Onkologie a hematologie
- 2016 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Docetaxel-Kabazitaxel-Enzalutamide Sequence vs Docetaxel-Enzalutamide Sequence in Patients with Metastatic Cancer Resistant Prostate Cancer
-enzalutamide and docetaxel-enzalutamide. Patients and Methods: A total of 11 patients were treated with docetaxel-kabazitaxel-enzalutamide, 24 patients were treated with docetaxel-enzalutamide. The dosing was stan...
Oncology
- 2017 •
- Jost
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Enzalutamide and abiraterone in the treatment of metastatic castration-resistant prostate cancer after chemotherapy
Aim: Enzalutamide and abiraterone represent new therapeutical options of enzalutamide or abiraterone in the postchemo indication in patients with mCRPC. Patients or more lines of chemotherapy. Twenty-three patients were treated by <...
FD - Onkologie a hematologie
- 2016 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Enzalutamide in treatment of the metastatic castrate resistant prostate cancer
extending patient overal survival. Enzalutamide targets multiple steps in the androgen cancer, enzalutamid has become a cornerstone of the treatment due to results of enzalutamid in the treatment of this malignancy....
Oncology
- 2019 •
- JSC •
- Link
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Výsledek na webu
Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors a case report of an elderly patient with mCRPC treated with enzalutamide with very of enzalutamide in full doses resulted in a very...
Oncology
- 2024 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Enzalutamide in treatment of metastatic castrate resistant metastatic prostate cancer
extending patient overal survival. Enzalutamide targets multiple steps in the androgen cancer, enzalutamide has become a cornerstone of the treatment due to results of enzalutamide in the treatment of this malignancy....
Oncology
- 2019 •
- O
Rok uplatnění
O - Ostatní výsledky
Achieving complete remission after sequential treatment with docetaxel‑cabazitaxel enzalutamide in a patient with metastatic castration‑resistant prostate cancer
In our case report, we present a case of a patient initially with locally-regionally advanced prostate cancer. The complete remission was achieved after sequential treatment of docetaxel-cabazitaxel-enzalutamide, with maintaining good qualit...
Oncology
- 2019 •
- Jost •
- Link
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Výsledek na webu
Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
with metastatic castration-resistant prostate cancer (mCRPC) treated by enzalutamide with mCRPC treated by enzalutamide (55 patients) or abiraterone (11 patients) after previous therapy with docetaxel. The median follow-up was 31.2...
Oncology
- 2023 •
- JSC •
- Link
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Výsledek na webu
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 1-and 2-Year Open-label Follow-up Results
Background: Enzalutamide is an androgen receptor inhibitor with a demonstrated study of enzalutamide monotherapy in patients with hormone-naive prostate cancer and safety of enzalutamide monotherapy at 1 and 2 yr. Design, s...
FJ - Chirurgie včetně transplantologie
- 2015 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
- 1 - 10 out of 63